Comparative Pharmacology
Head-to-head clinical analysis: PARICALCITOL versus RAYALDEE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARICALCITOL versus RAYALDEE.
PARICALCITOL vs RAYALDEE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paricalcitol is a synthetic vitamin D analog that binds to the vitamin D receptor (VDR) in target tissues, including the parathyroid glands, kidneys, and intestines. It selectively activates VDR to suppress parathyroid hormone (PTH) secretion, reduce parathyroid cell proliferation, and modulate calcium and phosphate homeostasis with lower calcemic and phosphatemic effects compared to calcitriol.
Rayaldee (calcifediol) is a vitamin D3 analog that is converted to the active hormone calcitriol by 1-alpha-hydroxylase in the kidney. It acts as a vitamin D receptor agonist, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and suppressing parathyroid hormone (PTH) secretion. In CKD patients, it lowers elevated PTH levels.
0.04 to 0.1 mcg/kg intravenously bolus no more frequently than every other day during dialysis, or 1 to 4 mcg orally once daily.
30 mcg orally once daily at bedtime.
None Documented
None Documented
Clinical Note
moderateParicalcitol + Digoxin
"The risk or severity of adverse effects can be increased when Paricalcitol is combined with Digoxin."
Clinical Note
moderateParicalcitol + Hydrochlorothiazide
"Paricalcitol may increase the hypercalcemic activities of Hydrochlorothiazide."
Clinical Note
moderateParicalcitol + Bendroflumethiazide
"Paricalcitol may increase the hypercalcemic activities of Bendroflumethiazide."
Clinical Note
moderateParicalcitol + Methyclothiazide
Terminal elimination half-life is approximately 5-7 hours in healthy subjects, but may be prolonged to 14-20 hours in patients with renal impairment.
Terminal elimination half-life is approximately 14-19 hours, reflecting the extended-release formulation designed for once-daily dosing.
Primarily fecal (74%) via hepatobiliary excretion; renal elimination accounts for approximately 16% as unchanged drug.
Primarily fecal via biliary excretion (70-80%); renal excretion accounts for <10% of total clearance.
Category C
Category C
Vitamin D Analog
Vitamin D Analog
"Paricalcitol may increase the hypercalcemic activities of Methyclothiazide."